{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:24:36Z","timestamp":1761920676365,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["GZ-2014-11130"],"award-info":[{"award-number":["GZ-2014-11130"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The multi-drug resistance transporter ABCG2, a member of the ATP-binding cassette (ABC) transporter family, mediates the efflux of different immunotherapeutics used in multiple sclerosis (MS), e.g., teriflunomide (teri), cladribine, and mitoxantrone, across cell membranes and organelles. Hence, the modulation of ABCG2 activity could have potential therapeutic implications in MS. In this study, we aimed at investigating the functional impact of abcg2 modulation on teri-induced effects in vitro and in vivo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>T cells from C57BL\/6\u2009J wild-type (wt) and<jats:italic>abcg2<\/jats:italic>-knockout (KO) mice were treated with teri at different concentrations with\/without specific abcg2-inhibitors (Ko143; Fumitremorgin C) and analyzed for intracellular teri concentration (HPLC; LS-MS\/MS), T cell apoptosis (annexin V\/PI), and proliferation (CSFE). Experimental autoimmune encephalomyelitis (EAE) was induced in C57BL\/6J by active immunization with MOG<jats:sub>35\u201355<\/jats:sub>\/CFA. Teri (10\u2009mg\/kg body weight) was given orally once daily after individual disease onset.<jats:italic>abcg2<\/jats:italic>-mRNA expression (spinal cord, splenic T cells) was analyzed using qRT-PCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In vitro, intracellular teri concentration in T cells was 2.5-fold higher in<jats:italic>abcg2<\/jats:italic>-KO mice than in wt mice. Teri-induced inhibition of T cell proliferation was two\u00a0fold increased in<jats:italic>abcg2<\/jats:italic>-KO cells compared to wt cells. T cell apoptosis demonstrated analogous results with 3.1-fold increased apoptosis after pharmacological abcg2-inhibition in wt cells.<jats:italic>abcg2<\/jats:italic>-mRNA was differentially regulated during different phases of EAE within the central nervous system and peripheral organs. In vivo, at a dosage not efficacious in wt animals, teri treatment ameliorated clinical EAE in<jats:italic>abcg2<\/jats:italic>-KO mice which was accompanied by higher spinal cord tissue concentrations of teri.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Functional relevance of abcg2 modulation on teri effects in vitro and in vivo warrants further investigation as a potential determinant of interindividual treatment response in MS, with potential implications for other immunotherapies.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12974-019-1677-z","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T13:03:04Z","timestamp":1578488584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis"],"prefix":"10.1186","volume":"17","author":[{"given":"Lisa","family":"Thiele n\u00e9e Schrewe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Guse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Tietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Remlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seray","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiomara","family":"Pedreiturria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hoepner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Pistor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk M.","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"L\u00fchder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Wiese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"1677_CR1","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1124\/dmd.118.083030","volume":"46","author":"N Heyes","year":"2018","unstructured":"Heyes N, Kapoor P, Kerr ID. Polymorphisms of the Multidrug Pump ABCG2: A systematic review of their effect on protein expression, function, and drug pharmacokinetics. Drug Metab Dispos. 2018;46:1886\u201399.","journal-title":"Drug Metab Dispos."},{"key":"1677_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18:452\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1677_CR3","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41586-018-0680-3","volume":"563","author":"I Manolaridis","year":"2018","unstructured":"Manolaridis I, Jackson SM, Taylor NMI, Kowal J, Stahlberg H, Locher KP. Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states. Nature. 2018;563:426\u201330.","journal-title":"Nature"},{"key":"1677_CR4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/ard.2007.086264","volume":"68","author":"E Kis","year":"2009","unstructured":"Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009;68:1201\u20137.","journal-title":"Ann Rheum Dis."},{"key":"1677_CR5","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/brain\/awp164","volume":"132","author":"S Cotte","year":"2009","unstructured":"Cotte S, Von Ahsen N, Kruse N, Huber B, Winkelmann A, Zettl UK, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain. 2009;132:2517\u201330.","journal-title":"Brain."},{"issue":"3","key":"1677_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40262-018-0695-9","volume":"58","author":"Robert Hermann","year":"2018","unstructured":"Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A. The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis. Clin Pharmacokinet. 2018; Available from: https:\/\/doi.org\/10.1007\/s40262-018-0695-9.","journal-title":"Clinical Pharmacokinetics"},{"key":"1677_CR7","unstructured":"European Medicines Agency. Summary of Product Characteristics (last updated 27\/03\/2019) [Internet]. 2013. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aubagio-epar-product-information_en.pdf"},{"key":"1677_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/6198530","volume":"2017","author":"PK Coyle","year":"2017","unstructured":"Coyle PK. Pharmacogenetic biomarkers to predict treatment response in multiple sclerosis: current and future perspectives. Mult Scler Int. 2017;2017:1\u201310.","journal-title":"Mult Scler Int"},{"key":"1677_CR9","doi-asserted-by":"crossref","unstructured":"Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2018; Available from: http:\/\/www.nature.com\/articles\/s41582-018-0082-z.","DOI":"10.1038\/s41582-018-0082-z"},{"key":"1677_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/1756285617722500","volume":"10","author":"AE Miller","year":"2017","unstructured":"Miller AE. Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience. Ther Adv Neurol Disord. 2017;10:381\u201396.","journal-title":"Ther Adv Neurol Disord."},{"issue":"490","key":"1677_CR11","doi-asserted-by":"publisher","first-page":"eaao5563","DOI":"10.1126\/scitranslmed.aao5563","volume":"11","author":"Luisa Klotz","year":"2019","unstructured":"Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, et al. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Sci Transl Med. 2019;11 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31043571.","journal-title":"Science Translational Medicine"},{"issue":"3","key":"1677_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00401-019-02018-8","volume":"138","author":"Robert Hoepner","year":"2019","unstructured":"Hoepner R, Bagnoud M, Pistor M, Salmen A, Briner M, Synn H, et al. Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. Acta Neuropathol. Springer Berlin Heidelberg; 2019; Available from: https:\/\/doi.org\/10.1007\/s00401-019-02018-8","journal-title":"Acta Neuropathologica"},{"key":"1677_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/npp.2008.145","volume":"34145","author":"JE Merrill","year":"2009","unstructured":"Merrill JE. In vitro and in vivo pharmacological models to assess demyelination and remyelination. Neuropsychopharmacol Rev. 2009;34145:55\u201373.","journal-title":"Neuropsychopharmacol Rev."},{"key":"1677_CR14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.bcp.2015.08.111","volume":"98","author":"C Redaelli","year":"2015","unstructured":"Redaelli C, Gaffarogullari EC, Brune M, Pilz C, Becker S, Sonner J, et al. Toxicity of teriflunomide in aryl hydrocarbon receptor deficient mice. Biochem Pharmacol. 2015;98:484\u201392.","journal-title":"Biochem Pharmacol."},{"key":"1677_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1538\/expanim.14-0079","volume":"64","author":"A Seno","year":"2015","unstructured":"Seno A, Maruhashi T, Kaifu T, Yabe R, Fujikado N, Ma G, et al. Exacerbation of experimental autoimmune encephalomyelitis in mice deficient for DCIR, an inhibitory C-type lectin receptor. Exp Anim. 2015;64:109\u201319.","journal-title":"Exp Anim."},{"key":"1677_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bbi.2018.06.014","volume":"73","author":"S Tietz","year":"2018","unstructured":"Tietz S, P\u00e9rinat T, Greene G, Enzmann G, Deutsch U, Adams R, et al. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis. Brain Behav Immun. 2018;73:3\u201320 Available from: https:\/\/doi.org\/10.1016\/j.bbi.2018.06.014.","journal-title":"Brain Behav Immun"},{"key":"1677_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/356607a0","volume":"356","author":"FA Harding","year":"1992","unstructured":"Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992;356:607\u20139.","journal-title":"Nature."},{"key":"1677_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jneuroim.2013.10.003","volume":"265","author":"L Li","year":"2013","unstructured":"Li L, Liu J, Delohery T, Zhang D, Arendt C, Jones C. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol. 2013;265:82\u201390.","journal-title":"J Neuroimmunol."},{"key":"1677_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/FTD.0000000000000302","volume":"38","author":"A Filali-Ansary","year":"2016","unstructured":"Filali-Ansary A, Lunven C, Turpault S, Beyer Y-J, O\u2019Brien A, Delfolie A, et al. Dried blood spot methodology in combination with liquid chromatography\/tandem mass spectrometry facilitates the monitoring of teriflunomide. Ther Drug Monit. 2016;38:471\u201382.","journal-title":"Ther Drug Monit."},{"key":"1677_CR20","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1161\/STROKEAHA.111.648923","volume":"43","author":"A Elali","year":"2012","unstructured":"Elali A, Urrutia A, Rubio-Araiz A, Hernandez-Jimenez M, Colado MI, Doeppner TR, et al. Apolipoprotein-E controls adenosine triphosphate-binding cassette transporters ABCB1 and ABCC1 on cerebral microvessels after methamphetamine intoxication. Stroke. 2012;43:1647\u201353.","journal-title":"Stroke."},{"key":"1677_CR21","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1517\/17425255.2013.800483","volume":"9","author":"MD Wiese","year":"2013","unstructured":"Wiese MD, Rowland A, Polasek TM, Sorich MJ, O\u2019Doherty C. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol. 2013;9:1025\u201335.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"1677_CR22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.brainres.2015.07.005","volume":"1628","author":"H Qosa","year":"2015","unstructured":"Qosa H, Miller DS, Pasinelli P, Trotti D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res. 2015;1628:298\u2013316.","journal-title":"Brain Res"},{"key":"1677_CR23","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/jcbfm.2012.47","volume":"32","author":"CR Campos","year":"2012","unstructured":"Campos CR, Schr\u00f6ter C, Wang X, Miller DS. ABC transporter function and regulation at the blood-spinal cord barrier. J Cereb Blood Flow Metab. 2012;32:1559\u201366 Available from: http:\/\/journals.sagepub.com\/doi\/10.1038\/jcbfm.2012.47.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1677_CR24","unstructured":"European Medicines Agency. Aubagio: EPAR- Public assessment report. 2013. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/aubagio-epar-public-assessment-report_en.pdf"},{"key":"1677_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nm1186","volume":"11","author":"JW Jonker","year":"2005","unstructured":"Jonker JW, Merino G, Musters S, Van Herwaarden AE, Bolscher E, Wagenaar E, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med. 2005;11:127\u20139.","journal-title":"Nat Med."},{"key":"1677_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2012.00074","volume":"3","author":"G Kooij","year":"2012","unstructured":"Kooij G, Van Horssen J, Bandaru VVR, Haughey NJ, De Vries HE. The role of ATP-binding cassette transporters in neuro-inflammation: relevance for bioactive lipids. Front Pharmacol. 2012;3:1\u20136.","journal-title":"Front Pharmacol"},{"key":"1677_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12974-016-0715-3","volume":"13","author":"T Wostradowski","year":"2016","unstructured":"Wostradowski T, Prajeeth CK, Gudi V, Kronenberg J, Witte S, Brieskorn M, et al. In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia. J Neuroinflammation. 2016;13:250.","journal-title":"J Neuroinflammation"},{"key":"1677_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0779-0","volume":"14","author":"B Ambrosius","year":"2017","unstructured":"Ambrosius B, Faissner S, Guse K, von Lehe M, Grunwald T, Gold R, et al. Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity. J Neuroinflammation. 2017;14:1\u201310.","journal-title":"J Neuroinflammation"},{"key":"1677_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jneuroim.2014.11.017","volume":"278","author":"S Grey N\u00e9e Cotte","year":"2015","unstructured":"Grey N\u00e9e Cotte S, Salmen N\u00e9e Stroet A, von Ahsen N, Starck M, Winkelmann A, Zettl UK, et al. Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. J Neuroimmunol. 2015;278:277\u20139.","journal-title":"J Neuroimmunol"},{"key":"1677_CR30","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","volume":"22","author":"LA Doyle","year":"2003","unstructured":"Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22:7340\u201358.","journal-title":"Oncogene."}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1677-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-019-1677-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1677-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T10:09:51Z","timestamp":1665396591000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1677-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1677"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1677-z","relation":{},"ISSN":["1742-2094"],"issn-type":[{"type":"electronic","value":"1742-2094"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"14 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were reviewed and approved by the Veterinary Office of the Canton of Bern (permission number: BE 64\/16) or the North Rhine-Westphalia authorities for animal experimentation (permission number: 84-02.04.2015.A006). Human studies were approved by the local cantonal ethic committee Bern (KEK-BE 2017-00060).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LT received speaker honoraria and travel support from Sanofi Genzyme. KG is a former employee of Biogen, not related to this work. ST reports no competing interests. JR, XP, MP, FL, and SW report no disclosures. SD received compensation for activities with Sanofi Genzyme. RH received research and travel grants from Novartis and Biogen Idec. He also received speaker\u2019s honoraria from Biogen, Novartis, Merk and Almirall. AS received speaker honoraria and\/or travel compensation for activities with Almirall Hermal GmbH, Biogen, Merck, Novartis, Roche and Sanofi Genzyme, not related to this work. TT is an employee of Sanofi. BE received funding for a research project not related to this work. DMH reports no competing interests. He has received funding from the Deutsche Forschungsgemeinschaft (HE3173\/2-2). AC has received compensation for activities with Actelion, Almirall, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Roche, and Teva, all for university research funds. He has served as country principle investigator for teriflunomide phase III trials in Germany. He receives research support from the Swiss National Science Foundation, Biogen, Genzyme, and UCB. He serves in the editorial board for Clinical and Translational Neuroscience and the Journal of International Medical Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}